Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Spinal Muscular Atrophy Treatment Market is anticipated to grow at a CAGR of ~13% by 2026Spinal Muscular Atrophy refers to a group of hereditary diseases that damages and kills specialized nerve cells in the brain and spinal cord (called motor neurons).
Increasing R&D Activities for the Treatment of Spinal Muscular Atrophy Drives the Market Currently, there is no known cure for Spinal Muscular Atrophy (SMA). However, multiple treatments are available to help slow the progression of the disease, relieve symptoms, and manage potential complications. In addition to these approved treatments, several other treatments are being tested in clinical trials. For instance,
Growing Adoption of Spinal Muscular Atrophy Treatment in Babies Fuels the Spinal Muscular Atrophy Treatment Market Demand Spinal muscular atrophy affects approximately 1 in 11,000 babies born worldwide each year and is the most common genetic cause of death in infants. Children might suffer from a variety of SMAs. They vary in the age when symptoms initially appear, the seriousness of symptoms, and how symptoms get worse. Early detection and treatment of SMA are important as studies suggest that therapy is most effective when started in the first few months of life. Depending on the symptoms, treatment options for children include targeted therapy, respiratory therapy, nutritional therapy, muscle & joint therapy, and medications. Numerous innovative drugs have recently been developed that improve or ameliorate symptoms in many children. Explore Premium Report on Spinal Muscular Atrophy Treatment Market @ https://meditechinsights.com/ Competitive Landscape Analysis of Spinal Muscular Atrophy Treatment Market The global spinal muscular atrophy treatment market is marked by the presence of established key players such as Astellas Pharma Inc., AstraZeneca PLC, Biogen Inc., and Salarius Pharmaceuticals Inc., among others. End
|
|